PubMed
GHRP-2: a GH secretagogue for clinical use
Bowers CY. J Pediatr Endocrinol Metab. 1997
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 3% · Unfavorable overall 94%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 100–400 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 79% said they felt similar to their last entry, 21% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 180 days · Based on 24 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 0% · Mixed 17% · Unfavorable overall 83%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0–25 mcg · Most common: 0–25 mcg
Reports cluster around 0–25 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Published sources linked on the GHRP-2 and Pentosan Polysulfate wiki pages.
PubMed
Bowers CY. J Pediatr Endocrinol Metab. 1997
PubMed
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
FDA Drug Label
Janssen Pharmaceuticals. FDA Drug Label. 1996
PubMed
Bannuru RR, Osani MC, Vaysbrot EE, et al. Osteoarthritis Cartilage. 2020
PubMed
Siddiq MAB, Oo WM, Hunter DJ. Joint bone spine. 2024
PubMed
Ghosh P. Seminars in arthritis and rheumatism. 1999